Global Companion Animal Vaccines Market: By Product Type (Canine Vaccines, Feline Vaccines, Avian Vaccines, and Equine Vaccines), By Disease Type (Canine Distemper, Canine Parvovirus, Feline Rabies and Others), By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Conjugate Vaccines, DNA Vaccines, and Subunit Vaccines), Distribution Channel (Veterinary Pharmacies, Veterinary Hospitals, Veterinary Clinics, and E-Commerce) and Geography - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

September 2017 | 191 pages | ID: G43CF9FCB73EN
Precision Business Insights (PBI)

Abstracts

Global Companion Animal Vaccines Market Report Description:

Companion animal vaccines market report gives comprehensive outlook on companion animal vaccines across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on companion animal vaccines market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, disease type, vaccine type, distribution channel, and geographic regions. This report studies companion animal vaccines market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, companion animal vaccines market report includes animal demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed companion animal vaccines market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the companion animal vaccines market report include suppliers, manufacturers, marketers, policy makers, and veterinary healthcare service providers engaged in manufacturing and supply of companion animal vaccines.


Global Companion Animal Vaccines Market:

Global companion animal vaccines market estimated to be valued US$ 2406 Mn in 2017 and poised to grow at CAGR of 7.8% over 2017-2023. Market for companion animal vaccines projected to reach US$ 3767 Mn by 2023 owing to rising human and companion animals bondage by means of adoption across the globe.

Increased awareness about pet health among pet owners projected to create market demand for companion animal vaccines over the forecast period

There has been a rise in awareness regarding pet health among pet owners across the developed and developing economies expected to drive market revenue growth over the forecast period. Moreover, several studies on human and companion animals’ interactions showed that association with companion animals results in positive health benefits. Therefore, it is essential to veterinarians and caregivers to give utmost attention to companion animal health as companion animals are primary source of zoonotic diseases spread to humans and vice versa, this is expected to create significant market demand for companion animal vaccines over the forecast period.

Increasing per pet expenditure in recent times expected to drive market revenue growth

Several respondents and pet owners reveled that pet expenditure is increasingly becoming integral part of their monthly expenditure and companion animals are part of several families across the developed and developing economies. Moreover, rising interactions between pets and human beings prompting the care givers and pet owners to adopt better healthcare services to the companion animals this is projected to drive market revenue growth over the forecast period.

North America market leads the global companion animal vaccines market

North America market leads the global companion animal health vaccines and projected to remain same over the forecast period owing to large pet ownership. According to data from American Pet Products association as of 2016, around 40% of households owned one or the other pet animals. Europe companion animal vaccines market holds significant share in global companion animal vaccines market. Increased product introduction in Europe like vaccine against Leishmania infantum, the causal agent of canine leishmaniosis which is significant breakthrough against zoonotic disease is one of the factors driving the market positively.

COMPETITION ASSESSMENT

Key players profiles in the global companion animal vaccines market include:

• Bayer AG (Germany)
• Boehringer Ingelheim GmbH (Germany)
• Ceva Santé Animale (France)
• Eli Lilly and Company (U.S)
• Heska Co. (U.S)
• Hester biosciences (India)
• Merck & Co., Inc. (U.S)
• Vétoquinol S.A. (France)
• Virbac S.A. (France)
• Zoetis Inc. (U.S)

Players in the companion animal vaccines market are launching the products in the market to garner larger market share. For instance, in 2016, Merck Animal Health launched Nobivac Canine Flu Bivalent vaccine in U.S market – the first vaccine to aid in the control of disease associated with both canine influenza virus (CIV) H3N2 and canine influenza virus H3N8.

KEY FINDINGS OF THE REPORT:

• Companion animal vaccines market expanding at 7.8% CAGR over 2017 to 2023 to reach market value of US$ 3767 Mn by 2023 owing to increased adoption pet animals and rising zoonotic diseases
• Based on product type canine vaccine accounted for larger market revenue share in 2016 and projected gain larger market revenue share over the forecast period
• Veterinary clinics distribution channel is the prime source for companion vaccines across the globe and expected to remain attractive over the forecast period
• Players focusing on launching products to retain market position in global companion animal vaccines market

KEY FEATURES OF THE REPORT:

• The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

DETAILED SEGMENTATION

By Product Type

• Canine Vaccines
• Feline Vaccines
• Avian Vaccines
• Equine Vaccines

By Disease Type

• Canine Distemper
• Canine Parvovirus
• Feline Rabies
• Others

By Vaccine Type

• Live Attenuated Vaccines
• Inactivated Vaccines
• Recombinant vaccines
• Toxoid vaccines
• Conjugate Vaccines
• DNA Vaccines
• Subunit Vaccines

Distribution Channel

• Veterinary Pharmacies
• Veterinary Hospitals
• Veterinary Clinics
• E-Commerce

Geography

• North America
• U.S
• Canada
• Europe
• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Venezuela
• Rest of Latin America
• Middle East and Africa (MEA)
• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa Rest of MEA

Contents

1. RESEARCH METHODOLOGY

1.1. Secondary and Primary research
  1.1.1. Secondary Sources
  1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms

2. SCOPE OF STUDY

2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study

3. EXECUTIVE SUMMARY

4. GLOBAL COMPANION ANIMAL VACCINES MARKET DYNAMIC FACTORS

4.1. Drivers
  4.1.1. Economic Drivers
  4.1.2. Demand Side Drivers
  4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends

5. UNIQUE FEATURES OF THE REPORT

5.1. Competition analysis
  5.1.1. Dash board of top players
  5.1.2. Financial Analysis
  5.1.3. Product & Services
  5.1.4. Key Developments
  5.1.5. Major Strategies
  5.1.6. SWOT Analysis
5.2. Technological advancements in companion animal Vaccines market
5.3. Recent investments in the industry
5.4. Regulatory landscape
  5.4.1. U.S.
  5.4.2. Europe
5.5. PESTLE analysis
5.6. Porter’s analysis

6. GLOBAL COMPANION ANIMAL VACCINES MARKET, BY PRODUCT, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Companion Animal Vaccines
  6.1.1. Canine Vaccines
    6.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
  6.1.2. Feline Vaccines
    6.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
  6.1.3. Avian Vaccines
    6.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
  6.1.4. Equine Vaccines
    6.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7. GLOBAL COMPANION ANIMAL VACCINES MARKET FORECAST, BY DISEASE, 2012 - 2016 AND FORECAST, 2017 – 2023

7.1. Companion Animal Diseases
  7.1.1. Canine Distemper
    7.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
    7.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
  7.1.2. Canine Parvovirus
    7.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
    7.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
  7.1.3. Feline Rabies
    7.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
    7.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
  7.1.4. Others
    7.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
    7.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8. GLOBAL COMPANION ANIMAL VACCINES MARKET FORECAST, BY VACCINES TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023

8.1. Live Attenuated Vaccines
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Inactivated Vaccines
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Recombinant Vaccines
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.4. Toxoid Vaccines
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.5. Conjugate Vaccines
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.6. DNA Vaccines
  8.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.7. Subunit Vaccines
  8.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9. GLOBAL COMPANION ANIMAL VACCINES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023

9.1. Veterinary Hospitals
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.2. Veterinary Clinics
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.3. Veterinary Pharmacies
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.4. Others
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

10. COMPANION ANIMAL VACCINES MARKET FORECAST, BY REGION ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. North America Companion Animal Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.1.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.1.1. Companion Animal Vaccines
      10.1.1.1.1. Canine Vaccines
      10.1.1.1.2. Feline Vaccines
      10.1.1.1.3. Avian Vaccines
      10.1.1.1.4. Equine Vaccines
  10.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.2.1. Companion Animal Diseases
      10.1.2.1.1. Canine Distemper
      10.1.2.1.2. Canine Parvovirus
      10.1.2.1.3. Feline Rabies
      10.1.2.1.4. Others
  10.1.3. Vaccines Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.3.1. Live Attenuated Vaccines
    10.1.3.2. Inactivated Vaccines
    10.1.3.3. Recombinant Vaccines
    10.1.3.4. Toxoid Vaccines
    10.1.3.5. Conjugate Vaccines
    10.1.3.6. DNA Vaccines
    10.1.3.7. Subunit Vaccines
  10.1.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.4.1. Veterinary Pharmacies
    10.1.4.2. Veterinary Hospitals
    10.1.4.3. Veterinary Clinics
    10.1.4.4. E-Commerce
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.5.1. U.S.
    10.1.5.2. Canada
10.2. Europe Companion Animal Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.2.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.1.1. Companion Animal Vaccines
      10.2.1.1.1. Canine Vaccines
      10.2.1.1.2. Feline Vaccines
      10.2.1.1.3. Avian Vaccines
      10.2.1.1.4. Equine Vaccines
  10.2.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.2.1. Companion Animal Diseases
      10.2.2.1.1. Canine Distemper
      10.2.2.1.2. Canine Parvovirus
      10.2.2.1.3. Feline Rabies
      10.2.2.1.4. Others
  10.2.3. Vaccines Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.3.1. Live Attenuated Vaccines
    10.2.3.2. Inactivated Vaccines
    10.2.3.3. Recombinant Vaccines
    10.2.3.4. Toxoid Vaccines
    10.2.3.5. Conjugate Vaccines
    10.2.3.6. DNA Vaccines
    10.2.3.7. Subunit Vaccines
  10.2.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.4.1. Veterinary Pharmacies
    10.2.4.2. Veterinary Hospitals
    10.2.4.3. Veterinary Clinics
    10.2.4.4. E-Commerce
  10.2.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.5.1. Germany
    10.2.5.2. UK
    10.2.5.3. France
    10.2.5.4. Spain
    10.2.5.5. Italy
    10.2.5.6. Russia
    10.2.5.7. Poland 10.2.5.8. Rest of Europe
10.3. Asia-Pacific Companion Animal Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.3.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.1.1. Companion Animal Vaccines
      10.3.1.1.1. Canine Vaccines
      10.3.1.1.2. Feline Vaccines
      10.3.1.1.3. Avian Vaccines
      10.3.1.1.4. Equine Vaccines
  10.3.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.2.1. Companion Animal Diseases
      10.3.2.1.1. Canine Distemper
      10.3.2.1.2. Canine Parvovirus
      10.3.2.1.3. Feline Rabies
      10.3.2.1.4. Others
  10.3.3. Vaccines Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.3.1. Live Attenuated Vaccines
    10.3.3.2. Inactivated Vaccines
    10.3.3.3. Recombinant Vaccines
    10.3.3.4. Toxoid Vaccines
    10.3.3.5. Conjugate Vaccines
    10.3.3.6. DNA Vaccines
    10.3.3.7. Subunit Vaccines
  10.3.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.4.1. Veterinary Pharmacies
    10.3.4.2. Veterinary Hospitals
    10.3.4.3. Veterinary Clinics
    10.3.4.4. E-Commerce
  10.3.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.5.1. Japan
    10.3.5.2. China
    10.3.5.3. India
    10.3.5.4. ASEAN
    10.3.5.5. Australia & New Zealand 10.3.5.6. Rest of Asia-Pacific
10.4. Latin America Companion Animal Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.4.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.1.1. Companion Animal Vaccines
      10.4.1.1.1. Canine Vaccines
      10.4.1.1.2. Feline Vaccines
      10.4.1.1.3. Avian Vaccines
      10.4.1.1.4. Equine Vaccines
  10.4.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.2.1. Companion Animal Diseases
      10.4.2.1.1. Canine Distemper
      10.4.2.1.2. Canine Parvovirus
      10.4.2.1.3. Feline Rabies
      10.4.2.1.4. Others
  10.4.3. Vaccines Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.3.1. Live Attenuated Vaccines
    10.4.3.2. Inactivated Vaccines
    10.4.3.3. Recombinant Vaccines
    10.4.3.4. Toxoid Vaccines
    10.4.3.5. Conjugate Vaccines
    10.4.3.6. DNA Vaccines
    10.4.3.7. Subunit Vaccines
  10.4.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.4.1. Veterinary Pharmacies
    10.4.4.2. Veterinary Hospitals
    10.4.4.3. Veterinary Clinics
    10.4.4.4. E-Commerce
  10.4.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.5.1. Brazil
    10.4.5.2. Mexico
    10.4.5.3. Argentina
    10.4.5.4. Venezuela
    10.4.5.5. Rest of Latin America
10.5. Middle East & Africa (MEA) Companion Animal Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.5.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.1.1. Companion Animal Vaccines
      10.5.1.1.1. Canine Vaccines
      10.5.1.1.2. Feline Vaccines
      10.5.1.1.3. Avian Vaccines
      10.5.1.1.4. Equine Vaccines
  10.5.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.2.1. Companion Animal Diseases
      10.5.2.1.1. Canine Distemper
      10.5.2.1.2. Canine Parvovirus
      10.5.2.1.3. Feline Rabies
      10.5.2.1.4. Others
  10.5.3. Vaccines Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.3.1. Live Attenuated Vaccines
    10.5.3.2. Inactivated Vaccines
    10.5.3.3. Recombinant Vaccines
    10.5.3.4. Toxoid Vaccines
    10.5.3.5. Conjugate Vaccines
    10.5.3.6. DNA Vaccines
    10.5.3.7. Subunit Vaccines
  10.5.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.4.1. Veterinary Pharmacies
    10.5.4.2. Veterinary Hospitals
    10.5.4.3. Veterinary Clinics
    10.5.4.4. E-Commerce
  10.5.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.5.1. Gulf Cooperation Council (GCC) Countries
    10.5.5.2. Israel
    10.5.5.3. South Africa
    10.5.5.4. Rest of MEA

11. COMPETITION LANDSCAPE

11.1. Strategic Dashboard of Top Market Players
11.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  11.2.1. Bayer AG (Germany)
  11.2.2. Boehringer Ingelheim GmbH (Germany)
  11.2.3. Ceva Santé Animale (France)
  11.2.4. Eli Lilly and Company (U.S)
  11.2.5. Heska Co. (U.S)
  11.2.6. Hester biosciences (India)
  11.2.7. Merck & Co., Inc. (U.S)
  11.2.8. Vétoquinol S.A. (France)
  11.2.9. Virbac S.A. (France)
Zoetis Inc. (U.S)